Risk Assessment in Patients with Acute Myeloid Leukemia and a Normal Karyotype

Purpose: The recognition of a number of leukemia-specific cytogenetic abnormalities and their role as independent prognostic factors have provided considerable insights into leukemia pathogenesis and have paved the way to adopt risk-adapted treatment. However, ∼50% of newly diagnosed acute myeloid leukemia (AML) have a normal karyotype. There has therefore been much interest in identifying molecular markers that could help to improve the prognostic stratification of patients with normal-karyotype AML. Experimental Design: Consecutive untreated AML patients ( n = 67) from a single institution all with normal karyotype were analyzed for the presence of mutations in the myeloid transcription factor gene CEBPA (for CCAAT/enhancer binding protein-α), for internal tandem duplications (ITD) of the tyrosine kinase receptor gene FLT3 (for fms -like tyrosine kinase 3), and for expression of the BAALC gene (for brain and acute leukemia, cytoplasmic). Results: 17.9% of normal-karyotype AML had mutations in the CEBPA gene, and 28.4% had FLT3 -ITD; 65.7% (44 of 67) had high BAALC expression and 34.3% (23 of 67) had low BAALC expression. Patients with CEBPA mutations had a very favorable course of their disease. Median disease-free survival (DFS) and overall survival (OS) were 33.5 and 45.5 months, respectively, compared with 10 (e.g., 12 months in patients without CEBPA mutations; P = 0.0017; P = 0.0007). AML patients with FLT3 -ITD had significantly shorter median DFS ( P = 0.0328) and OS ( P = 0.0148) than patients without FLT3 -ITD. High BAALC expression predicted for a shorter DFS ( P = 0.0152) and OS ( P = 0.0210) compared with AML with low BAALC expression; 53.7% of normal-karyotype AML had neither FLT3 -ITD nor CEBPA mutations. We found that high BAALC expression in normal-karyotype AML with neither FLT3 -ITD nor CEBPA mutations (18 of 67) indicates adverse prognosis for both DFS and OS ( P = 0.0001; e.g., P = 0.0001) compared with the group with low BAALC expression and absent FLT3 -ITD and CEBPA mutations (18 of 67). Thus, BAALC expression represents a novel prognostic marker particularly for normal-karyotype AML patients with neither FLT3 -ITD nor CEBPA mutations. Conclusions: Assessment of CEBPA mutations, FLT3 -ITD, and BAALC expression permits to split normal-karyotype AML into clinically distinct subgroups.